Abstract: The present invention relates to novel metathesis catalysts with an imidazolidine-based ligand and to methods for making and using the same. The inventive catalysts are wherein: M is ruthenium or osmium; X and X1 are each independently an anionic ligand; L is a neutral electron donor ligand; and, R, R1 R6, R7, R8, and R9 are each independently hydrogen or a substituent selected for the group consisting of C1 C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 alkoxycarbonyl, C1-C20 alkyithiol, aryl thiol, C1-C20 alkylsulfortyl and C1-C20 alkylsulfinyl, the substituent optionally substituted with one or more moieties selected from the group consisting of C1-C20 alkyl, C1-C10 alkoxy, aryl, and a functional group. The inclusion of an imidazolidine ligand to the previously described ruthenium or osmium catalysts has been found to dramatically improve the properties of these complexes.

Abstract: The invention relates to a method for preparation of ruthenium-based carbene catalysts with a chelating alkylidene ligand (“Hoveyda-type catalysts”) by reacting a penta-coordinated ruthenium (II)-alkylidene complex of the type (L) (Py)X1X2Ru(alkylidene) with a suitable olefin derivative in a cross metathesis reaction. The method delivers high yields and is conducted preferably in aromatic hydrocarbon solvents. The use of phosphine-containing Ru carbene complexes as starting materials can be avoided. Catalyst products with high purity, particularly with low Cu content, can be obtained.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: Compounds comprising phosphorescent metal complexes comprising cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1?,2?-c]quinazoline ligands, or isoelectronic or benzannulated analogs thereof, are described. Organic light emitting diode devices comprising these compounds are also described.

Abstract: A platinum (II) complex of general formula (II), in which Ar1 is a 1,2-diazole ring, Ar2 is a pyridine ring, and Ar3 is a phenyl ring. Ar1, Ar2, and Ar3 together form a tridentate ligand coordinated to the platinum through atoms X, Y, and Z, respectively, and X, Y, and Z are independently carbon or nitrogen. V represents O, S, N, C, P, or Si, and W is an anion. In some cases, Ar3 is an anion and Ar1 and Ar2 are neutral; in other cases, Ar1 and Ar3 are neutral and Ar2 is an anion. The complexes emit in the UV to near IR range and are useful as emitters for organic light emitting devices.

Abstract: The present invention relates to phosphorescent (triplet-emitting) organometallic materials. The phosphorescent materials of the present invention comprise Ir(III)cyclometallated alkynyl complexes for use as triplet light-emitting materials. The Ir(III)cyclometallated alkynyl complexes comprise at least one cyclometallating ligand and at least one alkynyl ligand bonded to the iridium. Also provided is an organic light emitting device comprising an anode, a cathode and an emissive layer between the anode and the cathode, wherein the emissive layer comprises a Ir(III)cyclometallated alkynyl complex as a triplet emitting material.

Abstract: The invention is directed to aryl alkylidene ruthenium complexes and the use of these complexes as catalysts in metathesis reactions.

Abstract: Imidazo[1,2-f]phenanthridine compounds are provided. The compounds have a twisted aryl moiety further substituted by alkyl having four or more atoms. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

Abstract: A compound according to the present invention is represented by the general formula (1): as defined herein. This makes it possible to provide (i) a novel compound that exhibits a practically sufficient light-emitting property not only in a case where the novel compound is used as a luminescent dopant, but also in a case where the novel compound is used solely, and (ii) use of the novel compound.

Abstract: The invention provides emissive materials and organic light emitting devices using the emissive materials in an emissive layer disposed between and electrically connected to an anode and a cathode. The emissive materials include compounds with the following structure: wherein at least one of R8 to R14 is phenyl or substituted phenyl, and/or at least two of R8 to R14 that are adjacent are part of a fluorenyl group. The emissive materials have enhanced electroluminescent efficiency and improved lifetime when incorporated into light emitting devices.

Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Abstract: Cis and trans ruthenium complexes that can be used as catalysts for ring opening metathesis polymerisation (ROMP) are described. The complexes are generally square pyramidal in nature, having two anionic ligands X. Corresponding cationic complexes where one or both of the anionic ligands X are replaced by a non-co-ordinating anionic ligand are also described. Polymers such as polydicyclopentadiene (PDCPD) can be prepared using the catalysts.

Abstract: Novel heteroleptic iridium complexes are provided. These iridium complexes are useful compounds in OLED devices. The ligands for these novel complexes may be obtained using a new synthetic methodology that utilizes manganese dioxide.

Abstract: Embodiments herein generally relate to the use, devices, and compounds for generating singlet oxygen. In some embodiments, the singlet oxygen can be used for fluid purification and/or sterilization.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: An organic electroluminescence element comprising at least an emission layer sandwiched between an anode and a cathode, wherein the emission layer comprises a metal complex having a partial structure represented by Formula (1):

Abstract: A method for preparing a ruthenium carbene complex precursor includes reacting a ruthenium refinery salt with a hydrogen halide to form a ruthenium intermediate, and reacting the ruthenium intermediate with an L-type ligand to form the ruthenium carbene complex precursor. A method for preparing a ruthenium vinylcarbene complex includes converting a ruthenium carbene complex precursor into a ruthenium hydrido halide complex, and reacting the ruthenium hydrido halide complex with a propargyl halide to form the ruthenium vinylcarbene complex. A method for preparing a ruthenium carbene complex includes converting a ruthenium carbene complex precursor into a ruthenium carbene complex having a structure (PR1R2R3)2Cl2Ru?CH—R4, wherein R1, R2, R3, and R4 are alike or different, and wherein covalent bonds may optionally exist between two or more of R1, R2, and R3.

Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes, in particular as emitters.

Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: Novel heteroleptic iridium carbene complexes are provided, which contain at least two different carbene ligands. Selective substitution of the carbene ligands provides for phosphorescent compounds hat are suitable for use in a variety of OLED devices.

Abstract: The present invention provides new ruthenium complexes of Formula (1), which contain a chelate ring created by a halogen atom X. The invention concerns also a method for the preparation of the new ruthenium complexes and their application in metathesis reactions.

Abstract: A blue phosphorescence compound is disclosed. The blue phosphorescence compound represented by Chemical Formula 1 below.

Abstract: Novel polydentate carbene complexes of ruthenium and formulations containing the same are provided. Organic light emitting device containing the novel polydentate carbene complexes of ruthenium in an emissive layer are also provided. The novel polydentate carbene complexes of ruthenium may be particularly useful in OLEDs to provide devices having improved performance.

Abstract: Neutral ruthenium(II) complexes having at least one bidentate carbene coordinated to the ruthenium through a ruthenium-carbene bond are provided. Also provided are organic light emitting devices comprising the ruthenium(II) carbene complexes.

Abstract: Sulfur chelated ruthenium compounds represented by the following formula: wherein M indicates the ruthenium metal bound to a benzylidene carbon; R represents C1-C7 alkyl group or optionally substituted aryl; X1 and X2 each independently represent halogen; Y1 and Y2 each independently denote unsubstituted or alkyl-substituted phenyl; and Z independently represents hydrogen, electron withdrawing or electron donating substituent, with m being an integer from 1 to 4, and processes and compositions related thereto.

Abstract: Disclosed is a transition metal complex represented by the following formula (1): (wherein M represents a transition metal element; K represents an uncharged monodentate or bidentate ligand; L represents a monodentate or bidentate monoanionic or dianionic ligand; m and o represent an integer from 0 to 5; n represents an integer from 1 to 3; p represents an integer from 0 to 4; W— represents a counterion; and Y1 to Y4, R1, and R2 each independently represent a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, an aralkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, or an alkoxy group).

Abstract: A light-emitting element in which a light-emitting layer contains an organic compound capable of emitting phosphorescence is provided. A light-emitting element which can have low driving voltage, high current efficiency, or a long lifetime is provided. In a light-emitting element in which a light-emitting layer is interposed between a pair of electrodes, the light-emitting layer contains an organic compound. The organic compound has a 1,2,4-triazole skeleton, a phenyl skeleton, an arylene skeleton, and a Group 9 metal or a Group 10 metal. The nitrogen atom at the 4-position of the 1,2,4-triazole skeleton coordinates to the Group 9 metal or the Group 10 metal. The nitrogen atom at the 1-position of the 1,2,4-triazole skeleton is bonded to a phenyl skeleton. The arylene skeleton is bonded to the 3-position of the 1,2,4-triazole skeleton and the Group 9 metal or the Group 10 metal.

Abstract: An unsubstituted or substituted phosphorescent compound of formula (I): Wherein: M is a transition metal; L in each occurrence is independently a mono- or poly-dentate ligand; R8 is H or a substituent; R9 and R10 are each independently selected from the group consisting of branched, linear or cyclic C1-20 alkyl wherein non-adjacent C atoms of the C1-20 alkyl may be replaced with —O—, —S—, —NR12—, —SiR122— or —COO— and one or more H atoms may be replaced with F or —NR122, wherein R12 is H or a substituent; R11 in each occurrence is independently H or a substituent, wherein two groups R11 may be linked to form a ring; x is at least 1; y is 0 or a positive integer; and z1, z2 and z3 are each independently 0 or a positive integer.

Abstract: Provided are a saturated N-heterocyclic carbene-ligand metal complex derivative, a method for preparing the same, and a method for preparing a silane compound by hydrosilylation using the same as a catalyst. To describe in more detail, the metal complex derivative has a saturated N-heterocyclic carbene derivative and an olefin ligand at the same time. A silane compound is prepared by hydrosilylation in the presence of the metal complex derivative as a catalyst. The provided metal complex derivative of the present invention has superior stability during hydrosilylation reaction and is capable of effectively performing the hydrosilylation reaction at low temperature even with small quantity. Further, a product with superior regioselectivity may be obtained. In addition, after the hydrosilylation reaction is completed, the metal complex derivative may be recovered and recycled.

Abstract: A phosphorescent metal complex is provided, which comprises a metallic central atom M and at least one ligand coordinated by the metallic central atom M, wherein the one metallic central atom M and the ligand form a six-membered metallacyclic ring. Additionally specified are a radiation-emitting component comprising a metal complex, and a process for preparing the metal complex.

Abstract: Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.

Abstract: A novel compound having the formula Os(L)n is disclosed, wherein Os is osmium(IV) metal, L is a ligand coordinating to the Os atom, and n is an integer from 1 to 6, wherein each L can be same or different, wherein at least one L is a multidentate ligand, and wherein the compound is neutral.

Abstract: Bridged cyclometalated carbene complexes, a process for preparing the bridged cyclometalated carbene complexes, the use of the bridged cyclometalated carbene complexes in organic light-emitting diodes, organic light-emitting diodes comprising at least one inventive bridged cyclometalated carbene complex, a light-emitting layer comprising at least one inventive bridged cyclometalated carbene complex, organic light-emitting diodes comprising at least one inventive light-emitting layer and devices which comprise at least one inventive organic light-emitting diode.

Abstract: Novel heteroleptic iridium carbene complexes are provided. The complexes have lower-than expected sublimation temperatures, which is beneficial for the processing of these materials in solid state applications. Selective substitution of the ligands provides for phosphorescent compounds that are suitable for use in a variety of OLED devices. The carbene complexes can also be used as materials in a hole blocking layer and/or an electron transport layer to improve device performance.

Abstract: An organic electroluminescence device material comprising a metal complex having a neopentyl group, for example, as shown below; and an organic electroluminescence device comprising a substrate having thereon a pair of electrodes and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein any one of the organic layer contains the organic electroluminescence device material.

Abstract: The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilizing two mono-anionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products.

Abstract: A compound is represented by the following formula (I): wherein N represents a nitrogen atom; C represents a carbon atom; Pt represents a platinum atom; Z1, Z4, Z5, and Z8 represent a carbon atom or a nitrogen atom; Z2, Z3, Z6, and Z7 represent a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom; Z11 and Z16 represent a carbon atom or a nitrogen atom; Z12, Z13, Z14, Z15, Z17, Z18, Z19, and Z20 represent a carbon atom, a nitrogen atom, an oxygen atom, or a sulfur atom; Y1 and Y2 represent a single bond, an oxygen atom, a sulfur atom, a nitrogen atom; A11 represents a divalent linking group; B1 and B2 represent a single bond or a divalent linking group.

Abstract: Novel organic compounds comprising a substituted anthracene or acridine ligand are provided. In particular, the compound includes an anthracene ligand substituted at the 9 and 10 positions. The compound may be used in organic light emitting devices to provide devices having improved efficiency and lifetime. In particular, these compounds may be especially beneficial for use in blue-emitting OLEDs.

Abstract: Novel heteroleptic iridium carbene complexes are provided, which contain phenyl imidazole moieties. In particular, ligands containing 2,4,6-trisubstituted N-phenyl imidazole fragments have highly desirable properties that make them suitable materials for use in OLED devices.

Abstract: The present invention relates to novel metathesis catalysts with an imidazolidine-based ligand and to methods for making and using the same. The inventive catalysts are wherein: M is ruthenium or osmium; X and X1 are each independently an anionic ligand; L is a neutral electron donor ligand; and, R, R1R6, R7, R8, and R9 are each independently hydrogen or a substituent selected for the group consisting of C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, aryl, C1-C20 alkoxycarbonyl, C1-C20 alkylthiol, aryl thiol, C1-C20 alkylsulfonyl and C1-C20 alkylsulfinyl, the substituted optionally substituted with one or more moieties selected from the group consisting of C1-C20 alkyl, C1-C10 alkoxy, aryl, and a functional group. The inclusion of an imidazolidine ligand to the previously described ruthenium or osmium catalysts has been found to dramatically improve the properties of these complexes.

Abstract: Stable, bent allenes, organometallic complexes of bent allenes are provided along with methods of conducting chemical processes such as olefin metathesis, comprising contacting an olefin substrate with an organometallic complex as described herein, under suitable conditions.

Abstract: Iridium compounds and their uses are disclosed herein. For example, carbazole containing iridium compounds are disclosed. The compounds are useful in many devices, including, but not limited to, electroluminescent devices.

Abstract: The present application relates to methods of preparing radiohalogenated compounds, to compounds useful in such methods and to radiohalogenated compounds useful for imaging and/or therapy.

Abstract: Synthesis of platinum(II) di(2-pyrazolyl)benzene chloride and analogs includes forming a 1,3-di-substituted benzene including two aromatic five-membered heterocycles, and reacting the 1,3-di-substituted benzene with an acidic platinum-containing solution to form a luminescent platinum(II) complex. The luminescent platinum(II) complex is capable of emitting blue and white light and can be used as an emitter in a light emitting device.

Abstract: Light emitting materials comprising multinuclear metal complexes comprising at least two metal atoms and a metal bridging ligand bound to said at least two metal atoms. It relates more particularly to a multinuclear complex of Formula (I): {-[L]2M-B-}n, wherein L is a bidentate ligand; M represents a transition metal having an atomic number of at least 40, and each M can be the same or different at each occurrence; B is a 2-connecting short metal bridging ligand bound to said at least two metal atoms, where the metal bridging ligand comprises coordinating atoms independently selected from the group consisting of nitrogen, phosphorous, carbon, oxygen, sulphur and selenium in 1,2 or 1,3 mutual position. (1,2-? or 1,3-? bonding mode); and n is an integer larger than 1.

Abstract: Described is a process for preparing platinum-carbene complexes.

Abstract: Disclosed are novel platinum-carbene complexes and use thereof as medicinal products.

Abstract: Iridium complexes with ligands containing twisted aryl groups having extended conjugation (i.e., the twisted aryl is substituted with an additional aryl group) and organic light emitting devices including the same are disclosed. The iridium complexes can be used in organic light emitting devices may provide improved stability color, lifetime and manufacturing.

Abstract: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C1 to C16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.

Abstract: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C1 to C16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.